Amendment to the Code
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
RPG Life Sciences reported audited FY 2025-26 results with revenue from operations of Rs 70,752 lakhs, up 8.3% from Rs 65,343 lakhs in FY 2024-25. However, profit after tax declined significantly to Rs 11,517 lakhs from Rs 18,324 lakhs in the previous year, a drop of about 37%. The decline was largely due to much lower exceptional items - Rs 390 lakhs this year versus Rs 8,260 lakhs last year. Last year's exceptional items included a Rs 12,623 lakhs profit from land assignment and Rs 1,633 lakhs fire-related insurance loss, while this year had Rs 9,893 lakhs land profit, Rs 2,475 lakhs net insurance income, Rs 1,169 lakhs labour code impact, and Rs 916 lakhs intangible asset write-off. The Board recommended a dividend of Rs 24 per share (300%) and appointed Dr. Pratit Samdani as Non-Executive Independent Director. The auditor issued an unmodified opinion.
The stock may face pressure due to 37% PAT decline despite positive operating cash flow of Rs 5,650 lakhs. The significant drop in exceptional items and one-time gains mask underlying operational weakness, while the 300% dividend signals management confidence.